NEOPLASMA 润色咨询

NEOPLASMA

出版年份:1957 年文章数:1026 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:4.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2021-03-10 ms7000000220050012

    求该杂志的endnote格式!

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2023-07-25 可乐雪碧 来自上海

    审稿速度:3.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤
    经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2015-04-04 springroll2000

    谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了
    We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again.
    The following decision has now been reached: Minor revision

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2023-08-26 ms7000001386761478

    审稿周期3月,版面费只收了彩图费用140欧

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2022-07-25 1442b0e3m32暂无昵称

    偏重的研究方向:肺癌
    经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。

    11

    展开11条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2023-07-25 可乐雪碧 来自上海

    审稿速度:3.0 | 投稿命中率:75.0
    偏重的研究方向:综合;肿瘤
    经验分享:前半年版面费900欧元,后半年1800欧元

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2023-02-21 ms1000000882251215

    需要原始数据吗

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2023-03-23 biyejiayou 来自辽宁省

    请问是从什么浏览器投稿呢?为啥投稿链接打不开

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2023-03-21 ms1000000596618881 来自广东省

    偏重的研究方向:血液学
    经验分享:请问你们都多久能检索的?

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=947271, encodeId=60fe94e271fc, content=求该杂志的endnote格式!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05205466067, createdName=ms7000000220050012, createdTime=Wed Mar 10 22:52:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149717, encodeId=3a6c2149e171d, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:3月5日投稿,期间审稿人给了14个问题,很详细回答,小修给了修改格式,6月25日,接受,前半年900欧元,后半年1800欧元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:41:14 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=510964, encodeId=bb5951096470, content=谢谢175.10.39.241,昨晚他们来邮件说小修,太激动了 <br> We would like to inform you that your manuscript could be published in NEOPLASMA, however only in the case minor revision of the manuscript will be performed. Below are the reviewer′s remarks. Would you be so kind and prepare the revised version of the manuscript and we will submit it to the reviewers again. <br> The following decision has now been reached: Minor revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=51fe1616150, createdName=springroll2000, createdTime=Sat Apr 04 07:26:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154694, encodeId=d4a42154694bb, content=审稿周期3月,版面费只收了彩图费用140欧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b48650005, createdName=ms7000001386761478, createdTime=Sat Aug 26 17:00:34 CST 2023, time=2023-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234670, encodeId=f7fe12346e07c, content=偏重的研究方向:肺癌<br>经验分享:6.15投稿,7.13修回,2审三天(周五回复,周一说接收)。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=61324841842, createdName=1442b0e3m32暂无昵称, createdTime=Mon Jul 25 18:48:30 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149716, encodeId=83112149e16b4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:综合;肿瘤<br>经验分享:前半年版面费900欧元,后半年1800欧元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Tue Jul 25 10:39:25 CST 2023, time=2023-07-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2115743, encodeId=1c812115e43fd, content=需要原始数据吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9e5636330, createdName=ms1000000882251215, createdTime=Tue Feb 21 16:48:27 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121414, encodeId=180721214148c, content=请问是从什么浏览器投稿呢?为啥投稿链接打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ce1a1619695, createdName=biyejiayou, createdTime=Thu Mar 23 20:20:38 CST 2023, time=2023-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2120902, encodeId=aff72120902f6, content=偏重的研究方向:血液学<br>经验分享:请问你们都多久能检索的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6155559036, createdName=ms1000000596618881, createdTime=Tue Mar 21 21:53:22 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=531599, encodeId=e6a1531599ba, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=447, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sun Jan 08 09:40:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]
    2017-01-08 jihuaijun1112

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享:今天刚接受,给大家分享一下经验。 我这篇文章是2016年3月份完成的,中间投了好几个杂志了,有些拒稿有些半年多没消息,后来找的Neoplasma这个,因为之前的拒稿经验,我花了一千多元让专业修稿公司改了一下语言方面的毛病。 2016年10月份投的稿,说实话也是没有信心,毕竟经历了七个多月的投稿,虽然这次润色了还是担心。大概一个月后收到意见,显示的是小修,看到这个还是挺兴奋的,因为咨询过投稿比较多的人,说小修基本上问题不大。两个编辑没人两个问题,一难一易:第一位是1、说一下为什么选择你所写的指标 2、如果可以通过培养细胞株在siRNA水平上进一步研究就更好了;第二位是1、建议进一步研究无病生存率 2、发现个别错词。 说实话,因为是第一次投,不敢自己随便回答,就通过导师介绍找了实验室主任,这个人在投稿方便肯定没得说,也是好几个外文杂志的评审。他让我把意见邮件发过去,让我周一下午去找他,当天去了后他开会,后来找了两次也没得人,时间不多了,最后还是自己回答的。 回答的时候需要先感谢一下,然后针对每一位评审意见回答。解释为什么选这个指标以及有错字这两个问题很简单,关于养细胞那个对我不现实了,也没时间了,所以就感谢意见-虚心接受-后续会做,关于生存率这个虽然有点麻烦,但还是可以完成的,就回去打电话随访一下,学习生存率方面的统计知识和作图,最后两周再次投稿。 到现在大概一个半月的时间,终于接受!前后包括小修共两个多月,相对来说还是比较快的。根据别人评论,好像见刊时间要挺久的,这个继续关注吧。 最后,给大家一点点我个人的体会:1,我们语言一般都不太过关,如果没有比较牛的师兄师姐或者导师给修改,建议还是能花点钱修改一下,否则会耽误很多时间在开会投稿上,因为有些杂志看到你的病句错句就不想看了。2,投稿的时候尽量按要求完成,尤其是图片和表格的格式要求,版面方面(包括如果标注作者,后面的利益冲突等等)建议下载两篇该杂志社最新的文章,比着修改,这个还是需要尽量仔细点,因为有可能这个一天的仔细能给你节省一个月的重新投稿的时间。3,如果有可能的话可以引用一两篇本杂志社的文章,大家自己体会原因。 其实我这将近一年的投稿过程中还有好多话,还是点到为止吧!希望对大家有一点帮助!

    4

    展开4条回复
共357条页码: 2/36页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分